Open access
Sep 2026
Immune checkpoint inhibitors (ICIs) have transformed Merkel cell carcinoma (MCC) outcomes, but most patients with MCC develop resistance. We identified T cell receptor (TCR)MCC1, a highly avid, HLA-A*02:01-restricted TCR targeting the Merkel cell polyomavirus (MCPyV) oncoprotein large-T antigen15-23. Seven patients wit...
Yuta Asano, Joshua R. Veatch, Cheng-Jung Sung et al.
· Science Translational Medici... · 0 citations
Save
{ copied = true; setTimeout(() => copied = false, 1500) })"
class="icon-btn" aria-label="Copy link">
{ copied = 'apa'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy APA
Copied ✓
{ copied = 'mla'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy MLA
Copied ✓
{ copied = 'bibtex'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy BibTeX
Copied ✓
Open access
Sep 2026
Despite decades of HIV-1 vaccine development, the clonal and cellular determinants of durable vaccine-induced T cell memory remain incompletely understood. Here, we combined antigen- specific T cell receptor (TCR) identification, longitudinal TCR sequencing, and single-cell multi- omics to characterize Env- and Gag-spe...
Guo-Yue Xu, Joshua X. Yee, Saskia Ilcisin et al.
· bioRxiv · 0 citations
Save
{ copied = true; setTimeout(() => copied = false, 1500) })"
class="icon-btn" aria-label="Copy link">
{ copied = 'apa'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy APA
Copied ✓
{ copied = 'mla'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy MLA
Copied ✓
{ copied = 'bibtex'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy BibTeX
Copied ✓
Open access
Sep 2026
Lenalidomide (Revlimid™), bortezomib (Velcade™), and dexamethasone, are used alone or in combination (RVd therapy) as first-line therapies for hematologic malignancies including the plasma cell dyscrasia, Multiple Myeloma (MM). The effects of RVd treatment on tumor cells have been documented, but little is known about...
Lucas T. Graybuck, L. Okada, Wei-Ling Chang et al.
· bioRxiv · 0 citations
Save
{ copied = true; setTimeout(() => copied = false, 1500) })"
class="icon-btn" aria-label="Copy link">
{ copied = 'apa'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy APA
Copied ✓
{ copied = 'mla'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy MLA
Copied ✓
{ copied = 'bibtex'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy BibTeX
Copied ✓